Airs on Lifetime TV at 7:30am EST

“To be a patient advocate is to arm yourself with the latest research, knowledge and resources and so far we’ve been able to touch the lives of millions of people through the 85 disease specific segments we’ve aired so far,” says Carri Levy, Creator – Behind The Mystery: Rare and Genetic Series.

DEERFIELD BEACH, Fla. (PRWEB)
September 18, 2019

Did you know that one in 10 Americans are living with a rare disease? Rare and genetic diseases often don’t get the attention they deserve and can have devastating effects on patients, their families and caregivers. That’s why for the past eight years, The Balancing Act’s series, Behind The Mystery: Rare and Genetic, has been bringing these often undiagnosed, misdiagnosed and complex medical conditions to the forefront by partnering with pharmaceutical and biotechnology companies who are on a mission to educate the public, which should lead to earlier diagnosis, treatment and provide a community for people suffering from these disorders.

The upcoming extended 30 minute “Special Edition” of Behind The Mystery: Rare and Genetic will examine ADPKD – Autosomal Dominant Polycystic Kidney Disease – a rare genetic disease that can lead to end state renal disease and BPDCN – Blastic Plasmacytoid Dendritic Cell Neoplasm, an aggressive blood cancer that is often times fatal if left untreated,. The special will witness real life conversations with experts at medical research institutions. Viewers will hear from patients who are living with these conditions and learn from their experiences. The show’s website (thebalancingact.com/rare) is a valuable 24/7 resource for patients and doctors who want to learn more about the over 85+ featured rare and genetic diseases.

The creator of the show, Carri Levy, is actively involved in the rare disease community because she knows first-hand how important it is to find answers for rare medical conditions, through her journey with her own daughter. Levy created Behind The Mystery: Rare and Genetic with her co-producer, Molly Mager, whose twin brother has an ultra-orphan disease, to help other families, like her own, navigate the difficult path toward diagnosis of one of the 7,000 rare and genetic diseases known.

The “Special Edition” Behind The Mystery: Rare and Genetic will air on Tuesday, September 24th on Lifetime at 7:30am EST. Previously aired episodes may be viewed at TheBalancingAct.com.

About The Balancing Act: The Balancing Act is a daily morning show created and produced by BrandStar that brings fresh ideas to today’s modern woman to help balance and enrich her life every day. Now in its ninth season, The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act, America’s premier half-hour show for women and about women, weekday mornings at 7:30 a.m. (ET/PT) on Lifetime®.

Share article on social media or email:

Image-Guided Electron Therapy

We consider Mobetron as a perfect platform for further development of our IORT program and to implement image guided 3D treatment planning.

SUNNYVALE, Calif. (PRWEB)
September 17, 2019

IntraOp Medical Corporation announced today that University Hospital Salzburg (SALK) Austria has purchased the IntraOp’s third generation Mobetron and advanced treatment planning software, to pursue implementing Image Guided Electron Therapy (IGET) for intraoperative radiation therapy (IORT) clinically.

The Paracelsus Medical University Hospital Salzburg has been a pioneering thought leader in IORT for more than 20 years. Professor Felix Sedlmayer, head of radiation oncology and president of the International Society of IORT (ISIORT) said: “We consider Mobetron as a perfect platform for further development of our IORT program and to implement image guided 3D treatment planning.”

Prof. Sedlmayer is the Principal Investigator in the ongoing HIOB trial (Hypofractionated Whole-Breast Irradiation preceded by Intra-Operative Radiotherapy with Electrons as anticipated Boost). HIOB is the largest prospective multi-institutional trial studying the benefits of electron IORT in the treatment of breast cancer.

“We are delighted to be partnering with Professor Sedlmayer and the team at University Hospital Salzburg and providing the most advanced IORT technology available today,” said Derek T. DeScioli, Chief Executive Officer of IntraOp Medical Corporation. “Their institution has been a pioneer in IORT from the beginning, and we look forward to working with them to advance the research and technology to the next level of sophistication.”

IntraOp will be providing to University Hospital Salzburg its third generation Mobetron technology including automatic soft docking, Prelude® IORT Management system and Radiance® 3D treatment planning as well high density radiotranslucent applicators compatible with Image Guided Electron Therapy.

About IntraOp Medical Corporation

IntraOp® is the leading innovator of electron radiation devices for treating cancer as an adjunct to invasive surgical procedures. As the developer and manufacturer of Mobetron®, IntraOp pioneered the world’s first portable, self-shielded LINAC used for electron-based Intraoperative Radiation Therapy (IORT). Over 20,000 patients in 16 countries have benefited from Mobetron IORT. Based in Sunnyvale, California, IntraOp is a cancer care company uniting radiation and surgical oncology in the fight against cancer. For more information, please visit https://intraop.com.

Product photography available upon request.

Share article on social media or email:

Lead investigator on the study, Sean Savitz, M.D.

DURHAM, N.C. (PRWEB)
September 17, 2019

Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. The information provided by the study could aid in developing new cellular therapies for this most common form of stroke — caused by a blocked artery — which affects over 13 million people each year, according to the World Health Organization.

The study in STEM CELLS is a follow up to the initial report on the first 10 patients in the trial, published in the Annals of Neurology in 2011. The STEM CELLS paper represents the total group of 25 patients.

Sean Savitz, M.D., director of the Institute for Stroke and Cerebrovascular Disease and professor of neurology at McGovern Medical School at UTHealth Houston, was lead investigator on the study. “Having found no clear evidence of harm to the initial 10 patients,” he said, “we broadened the inclusion criteria and enrolled additional patients. Our choice of cell type — bone marrow mononuclear cells (BM MNCs) – dose (10 million cells/kg), timing; route of administration; and the autologous approach was based on, and is in line with, growing evidence from animal stroke models and clinical evidence for possible treatment effects in our traumatic brain injury studies and other diseases.”

BM MNCs are attractive in regenerative medicine studies because they can be rapidly isolated; are enriched with hematopoietic, mesenchymal and endothelial progenitor cells; and permit autologous applications. Preclinical studies consistently indicate that MNCs improve outcome when administered within 72 hours of stroke onset and at least one clinical trial has shown they are not effective beyond seven days, the researchers said.

The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery. The cells migrate to the site of injury, release cytokines and other trophic factors, decrease proinflammatory and upregulate anti-inflammatory pathways, among other things. They also are easily amenable to autologous infusion, eliminating the need for immunosuppressive drugs.

“In contrast to the generation of autologous mesenchymal stem cells, another promising cell therapy,” added Dr. Savitz, “MNCs do not require passage in culture, which allows for testing in the early post-stroke time window.”

Each patient in the Savitz team’s study received an intravenous dose of their own BM MNCs within 72 hours after onset of their stroke. They were then followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.

“In the light of our findings,” said Dr. Savitz, “we believe that MNCs pose no additional harm in ischemic stroke patients when given during the acute phase, doses up to 10 million cells/kg are tolerated and it is feasible to perform a BM harvest and re-infusion of MNCs for a wide range of stroke patients. Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery.”

“New options to treat Ischemic stroke are desperately needed,” said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “This important clinical trial provides solid safety and feasibility data on which later trials can be built, using the patient’s own bone marrow stem/progenitor cells to potentially enhance recovery after ischemic stroke.”

The full article, “Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3080.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

Thanks to technology, people are living longer and healthier lives than ever before.

JUPITER, Fla. (PRWEB)
September 16, 2019

A new episode of Advancements with Ted Danson will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local listings for more information on this program.

The show will explore Credo Biomedical Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to developing advanced diagnostic technologies for the masses. Viewers will learn about Credo Biomedical’s POC Real-Time PCR platform, which provides medical professionals with molecular diagnostic results at the point-of-care, to make critical decisions at a cost level traditionally reserved for rapid test.

Learn how neurotechnology is helping people reach their potential and improve quality of life through brain simulation as the show educates about how Sound for Life is helping children and adults become more empowered and overcome learning, attention, speech and language, sensory and auditory challenges. The segment will also focus on two of its technologies; Forbrain® and Soundsory®.

The definition of addiction has evolved to be defined by the American Society of Addiction Medicine as a primary, chronic disease of brain reward, motivation, memory, and related circuitry. The segment will explore recent developments in neuro behavioral science and how it has progressed in recent years. Spectators will learn about Unity Behavioral Health’s dedication to using evidence-based treatment modalities, along with cutting-edge holistic therapies to make a difference in the lives of individuals living with addiction.

Watch to discover current global data storage issues and to see how Lyteloop Technologies, LLC. (Lyteloop) is helping overcome problems associated with scalability, access to physical sites, and cybersecurity. With a behind-the-scenes look, viewers will learn about Lyteloop’s new data storage method and how it is using technology to improve data storage and build hyperscale data centers in space.

“Thanks to technology, people are living longer and healthier lives than ever before,” said Chad Densen, production manager for DMG Productions and the Advancements series. “We look forward to highlighting how technology is advancing the fields of medicine, data storage, health, and more, in this exciting new episode.”

About Advancements and DMG Productions:

The Advancements television series is an information-based educational program, targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, and a team dedicated to education and advancement, DMG Productions consistently produces commercial-free, educational programming on which both viewers and networks depend.

For more information visit AdvancementsTV.com or call (866) 496-4065.

Share article on social media or email:

“We feel that with the addition of Maxx™ Ultra Cord, Royal Biologics will now offer one of the most expansive birth tissue portfolios in the industry. We have multiple options, sizes and variations to fit the needs of our customers.” – Salvatore Leo, CEO.

HACKENSACK, N.J. (PRWEB)
September 16, 2019

Royal Biologics, a leading manufacturer and distributor of orthobiologic and regenerative medicine solutions today has announced the U.S. commercial launch of Maxx™ Ultra Cord, a maximum natural thickness allograft derived from umbilical cord. Maxx™Ultra Cord provides an alternative from traditional placental layer membrane allografts by providing up to 8X thicker membrane options that can be sutured and offers excellent handling characteristics. Maxx Ultra Cord will join Royal Biologics’ robust portfolio of traditional and signature allograft products used to treat and heal a variety of conditions in multiple specialties.

Salvatore Leo, Chief Executive Officer of Royal Biologics states, “With the addition of Maxx™ Ultra Cord Royal Biologics will now offer a wide variety of allograft products used to treat various potential clinical applications such as spine & neurosurgery, foot & ankle, wound care and dermatology. We are excited to announce the U.S. commercial launch of Maxx Ultra Cord and are looking forward to continuing to bring multiple solution options to surgeons needs.”

Maxx™ Ultra Cord will be the first umbilical derived allograft to join Royal Biologics birth tissue portfolio which include its Amnio-Maxx™ family of traditional single and double layer Amniotic Placental allografts and Amnio Maxx RT and Cyro, its placental fluid based allograft options.

“We feel that with the addition of Maxx™ Ultra Cord, Royal Biologics will now offer one of the most expansive birth tissue portfolios in the industry. We have multiple options, sizes and variations to fit the needs of our customers.” – Salvatore Leo, CEO.

About Royal Biologics, LLC

Royal Biologics is a leading medical device and biologics company located in Hackensack, NJ. The company sells branded and licensed orthobiologics and stem cell therapy devices, and serves as the sales representatives for multiple spinal implant hardware product lines. Some of Royal’s branded products include Maxx-Cell, a proprietary bone marrow aspirate needle, and Amnio-Maxx, amniotic fluid and / or dual layered tissue used in spine and orthopedic procedures to promote wound healing and the regeneration of healthy tissue. For more information, please visit https://royalbiologics.com/

Share article on social media or email:

Beginning to offer digital pathology services a little over two years ago was the logical next step in offering best-in-class imaging and drug discovery services to our Clients

WHITEHOUSE STATION, N.J. (PRWEB)
September 16, 2019

When a lot of researchers think of Visikol, they think of the companies tissue clearing reagents and kits that allow for the complete 3D characterization of tissues through the use of confocal and light sheet microscopy. However, over the last few years, Visikol has transitioned into an imaging, image analysis and advanced cell culture focused contract research organization and today offers 3D tissue imaging as a service as well as digital pathology and 3D cell culture assays.

“To support our 3D tissue imaging services and products, we had developed a large suite of image analysis tools for both 2D and 3D data sets and began to apply these tools to help our Clients with their traditional 2D slide-based samples in 2017. Beginning to offer digital pathology services a little over two years ago was the logical next step in offering best-in-class imaging and drug discovery services to our Clients,” described Visikol Chief Executive Officer Dr. Michael Johnson.

Visikol offers pathology services to its Clients that include traditional H&E and IHC tissue preparation, slide scanning, fluorescent immunolabeling and multiplex labeling as well as imaging. All of these services can leverage either Visikol’s 3Screen™ image analysis software suite and/or evaluation by a board-certified Pathologist. At CAP this year, Visikol will be specifically focusing its presentations and data on immuno-oncology digital pathology and multiplex imaging. Visikol has demonstrated the ability to acquire a tremendous amount of information from a single slide and to answer many complex questions such as quantifying immune cell infiltration kinetics as well as how different immune cell sub-types behave.

Due to the cost of immuno-oncology therapeutics and consequently patient/animal data and samples, it is crucial to extract as much information as is possible from a single piece of tissue in order to better inform a clinical trial or a drug discovery program. Visikol partners closely with its pharmaceutical Clients to understand their specific research questions in order to create a labeling and data analysis plan for every tissue. Once wet tissues, FFPE blocks or slides are transferred to Visikol, the team at Visikol leverages its validated antibodies and immunolabeling approaches to ensure the highest quality imaging data is obtained through either slide scanning or automated confocal microscopy. After Visikol has generated a library of imaging data or a Client has transferred their own imaging data to Visikol, the team works to create and validate a robust image analysis pipeline for distilling this data down into the Clients desired endpoints.

As a company in the digital pathology space, Visikol is very unique with its expertise in advanced image analysis and multiplex imaging, but also because it leads the field in clinical digital pathology solutions. While there are several companies pursuing applications of machine learning and digital pathology in the clinic to address pathology limitations, Visikol was actually one of the first to accomplish this task through its development of digital pathology machine learning software to support the development of Enzyvant Therapeutic’s RVT-802.

Therefore, if you are interested in discussing your digital pathology projects in more detail with the field’s leading experts, stop by Visikol booth #216 or check out our services on our website.

About Visikol

Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Share article on social media or email:

JUPITER, Fla. (PRWEB)
August 14, 2019

An upcoming episode of Advancements with Ted Danson, scheduled to broadcast 4Q/2019, will explore how developments in microbiome therapeutics are helping to promote normal immune function in order to prevent and fight cancer. Check your local listings for more information.

Advancements will educate about the DECODE.DESIGN.CURE™ technology platform, which rapidly develops microbiome therapeutics in order to enable a lifetime without cancer.

Viewers will learn how Persephone Biome, Inc.’s (Persephone) world-class scientists utilize cutting-edge laboratory techniques in conjunction with artificial intelligence to better understand the large role that bacteria can play in the treatment of cancer.

“We are excited for the opportunity to share this innovative technology platform with the public and to educating about how it produces novel immunotherapies for cancer patients with severe unmet needs,” Said Stephanie Culler, Ph.D., Co-Founder, and CEO of Persephone Biome.

About Persephone Biome:

Persephone Biome takes a novel approach to improving the efficacy of current cancer therapies, leveraging the systemic impact of the gut microbiome on the human immune system. Persephone’s technology platform is based on collecting and analyzing gut microbiota samples from thousands of cancer patients, then using machine learning in conjunction with systems biology tools to understand the impact of gut microbes on patient prognosis. The results are used to design novel immunotherapies and companion diagnostics for cancers of unmet needs. The Company’s lead therapeutic candidate is planned to enter clinical trials in late 2020. For more information, visit: https://persephonebiome.com/.

About Advancements and DMG Productions:

The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world. 

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

 For more information, please visit http://www.AdvancementsTV.com or call Richard Lubin at 866-496-4065.

Share article on social media or email:

HOUSTON (PRWEB)
August 14, 2019

Representatives with MyBioGate announced that China Focus@Biotech Week will be held September 10 at the Boston Convention and Exhibition Center in Boston.

“We help innovative projects connect with Chinese pharma and investors in healthcare innovation,” said Miao Guo, Vice President of Operations and spokesperson for MyBioGate.

Guo went on to explain that as a part of Biotech Week Boston – the annual biotech festival at the No. 1 U.S. Life Science Cluster, China Focus @Biotech Week Boston provides a unique platform to inform, inspire, and foster cross-border partnership.

As for topics that will be covered during the event, Guo noted that attendees will be treated to KOLs sharing, company presentations and showcases, and networking opportunities.

“Meet investors, potential strategic partners, CRO/CMO providers, and regulatory experts for your China strategy in one place,” Guo stressed, before adding, “Additional topics will include the rise of the Chinese healthcare market and opportunities for investment and collaboration; regulatory reforms in China and the impact on cross-border partnership in the healthcare industry, and cell and gene therapy in and out of China, providing opportunities for collaboration.”

China has embraced a vigorously growing healthcare market in the past decade. Ever since joining ICH in 2017, China has seen increased clinical trials and accelerated new drug and device approval.

“For biotech and MedTech companies outside of China, finding the right partners and the right resources to bring your products to China is crucial to adapt to the difference in market acceptance, culture, regulation, reimbursement and more,” Guo said. In the meantime, Chinese biotechs are actively seeking global market entry opportunities and overseas partners.”

China Focus @Biotech Week Boston, according to Guo, is designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.

The company spokesperson went on to note that following the September event, its next event China Focus @Hamburg Germany, is slated for November 10.

For more information, please visit: https://events.mybiogate.com/biotechweekboston/

About China Focus

China Focus brings together investors, pharma leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate, and foster cross-border investment and collaboration in leading biopharma innovations. The pharma market in China grew to ~Rmb1,558bn (US$226bn) in 2018, at a CAGR of 10% in 2013-18, becoming the 2nd largest pharma market in the world.

Contact Details:

Feier Chen

Marketing Manager

7707 Fannin Street

Ste. 200

Houston, TX 77054

United States

Phone: (832) 497-2220

Email: feier.chen at mybiogate.com

Source: MyBioGate Inc. (event.mybiogate.com)

Share article on social media or email:

1 mm thick mouse brain labeled with NeuN and DAPI

We made our Tissue Clearing Ebook so that any researcher can easily adopt tissue clearing into their research workflow.

WHITEHOUSE STATION, N.J. (PRWEB)
August 19, 2019

Since the microscope was first introduced, researchers and clinicians have characterized tissues through the use of ultra-thin two dimensional slices which are placed on microscope slides, stained and visualized by a pathologist. However, this paradigm can be highly limited for complex tissues and complicated features such as vasculature and thus researchers in the last few years have begun to employ tissue clearing approaches combined with fluorescent labeling and three-dimensional microscopy (e.g. confocal microscopy, light sheet microscopy) to image tissues in 3D. Of all the tissue interrogation tools used in a laboratory, tissue clearing and 3D tissue imaging can be one of the most challenging and complex as it involves the marriage of multiple disparate disciplines. Proper execution of tissue clearing approaches requires an in-depth knowledge of fluorescent labeling, tissue processing, advanced microscopy, image processing and data processing.

While adopting tissue clearing can be challenging, at Visikol we have focused for the last few years on developing protocols, tools and reagents that are easy-to-use, rapid and inexpensive such that any researcher can quickly adopt them into their workflow. “To help support these efforts, we have developed a Tissue Clearing Ebook which provides a contextual overview to adopting any tissue clearing technique with feedback and lessons learned from hundreds of researchers,” described Visikol Product Manager Ian MacCloud. The Ebook is designed as a primer for adopting tissue clearing and gives researchers a break down of common pitfalls and key considerations to keep in mind during 3D imaging such as maximizing fluorescent signal, minimizing background fluorescence, when to use confocal or light sheet microscopy, which antibodies to use and how to process specific types of tissue (e.g. FFPE, frozen fresh) or 3D cell culture models (i.e. organoids, spheroids, microtisses).

“In working with lots of researchers, we have seen many of them get discouraged by tissue clearing in general as they see a 3D image of a whole mouse brain acquired with CLARITY, try to replicate the process in their lab and unfortunately have poor results. We really made the Ebook for these researchers as there are lots of mistakes researchers typically make in adopting tissue clearing such as jumping to a whole mouse brain before validating that their immunolabels can penetrate thick tissue or if they have enough fluorescent signal with thick samples,” described Visikol CSO Dr. Tom Villani. The goal of the tissue clearing Ebook is to provide a dense but short preview to tissue clearing that every researcher should review before adopting tissue clearing into their workflow. To download the Ebook click below:

TISSUE CLEARING EBOOK DOWNLOAD

About Visikol

Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Share article on social media or email: